Calliditas Therapeutics AB

Jefferies Presentation

Read more
About Us

Developing high-value products for patients in niche indications with significant unmet medical need

About Us
FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy

Read more

Investor presentation December 16, 8:00 ET / 14:00 CET
NOW FDA APPROVED

TARPEYO (budesonide) delayed release capsules

TARPEYO has been approved only by the US FDA and only for use in the United States. All information concerning TARPEYO on this website is intended solely for residents of the United States.

Discover Tarpeyo

Vision and Strategy

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Our Pipeline

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

View our pipeline